



vTv Therapeutics to Present at Two Upcoming Annual Investor Conferences

March 10, 2017

HIGH POINT, N.C.--(BUSINESS WIRE)--Mar. 10, 2017-- vTv Therapeutics Inc. (vTv) (Nasdaq: VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer's disease and diabetes, among other therapeutic areas, today announced that company management will present a corporate overview at two upcoming investor conferences.

Presentation Details:

ROTH Capital Partners 29th Annual Growth Stock Conference

- **Location:** Dana Point, California
- **Presentation Date:** Tuesday, March 14, 2017
- **Presentation Time:** 7:30 am PT

Needham & Co. 16th Annual Healthcare Conference

- **Location:** New York, New York
- **Presentation Date:** Tuesday, April 4, 2017
- **Presentation Time:** 4:20 pm ET

Live webcasts of the presentations can be accessed on the [News & Events](#) section of the website. The webcasts will be archived for 30 days following the presentations on the Company's website at www.vtvtherapeutics.com.

About vTv Therapeutics

vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. vTv has a pipeline of clinical drug candidates led by programs for the treatment of Alzheimer's disease and Type 2 diabetes as well as treatment of inflammatory disorders and the prevention of muscle weakness.



View source version on businesswire.com: <http://www.businesswire.com/news/home/20170310005614/en/>

Source: vTv Therapeutics Inc.

vTv Therapeutics Inc.
Michael Gibraltar, 646-378-2938
IR@vtvtherapeutics.com

or

Media:
Pure Communications Inc.
Katie Engleman, 910-509-3977
Katie@purecommunicationsinc.com